Myasthenia Gravis Epidemiology Forecast 2025-2034

Myasthenia gravis affects approximately 150 to 200 people per million worldwide. In the United States, this autoimmune disease affects an estimated 37 out of every 100,000 people. Various studies suggest that the rise in the number of cases is likely due to longer life expectancy or improved diagnostic methods.

Myasthenia Gravis Epidemiology Forecast Report Coverage

The “Myasthenia Gravis Epidemiology Forecast Report 2025-2034” offers comprehensive information on the prevalence and demographics of myasthenia gravis. It projects the future incidence and prevalence rates of myasthenia gravis across various populations. The study covers age, gender, and type as major determinants of the myasthenia gravis-affected population. The report highlights patterns in the prevalence of myasthenia gravis over time and projects future trends based on multiple variables.

The report provides a comprehensive overview of the disease, as well as historical and projected data on the epidemiology of myasthenia gravis in the 8 major markets.

Regions Covered

• The United States
• Germany
• France
• Italy
• Spain
• The United Kingdom
• Japan
• India

Myasthenia Gravis: Disease Overview

Myasthenia Gravis (MG) is a chronic autoimmune disorder that affects the communication between the nerves and muscles. Since muscles don’t receive proper signals from the nerves, muscle weakness occurs that worsens with activity. The condition is caused by the production of antibodies that block or destroy the receptors at the neuromuscular junction. Common symptoms include weakness in the arms, legs, and neck muscles and difficulty in swallowing, chewing, and speaking, among others. In severe cases, breathing problems are also observed.

Myasthenia Gravis: Treatment Overview

There is no cure for myasthenia gravis, but with proper treatment, symptoms can be managed. Anticholinesterase drugs, such as pyridostigmine, help in improving communication between nerves and muscles. Immunosuppressive medications such as steroids (prednisone) or azathioprine are prescribed for suppressing the overactive immune system that produces antibodies attacking the neuromuscular junction. Plasmapheresis can aid in temporarily improving symptoms, especially during severe episodes or crises.

Epidemiology

The myasthenia gravis epidemiology section offers information on the patient pool from history to the present as well as the projected trend for each of the 8 major markets. The publisher provides both current and predicted trends for myasthenia gravis by examining a wide range of studies. Additionally, the report covers the diagnosed patient pool for myasthenia gravis and their trends. The data is broken down into specific categories, such as total prevalent cases in males and females, and total diagnosed cases across different age groups and patient pools.

• According to an epidemiological study published in Frontiers in Neurology (2024), an analysis of a United States commercially/Medicare-insured cohort found an age- and sex-standardized incidence of 68.5 new cases per million person-years. The study also reported an adjusted prevalence of 316.4 per million in the cohort.
• Studies show that approximately 1 to 2 out of every 10 people with myasthenia gravis have a thymoma (a tumor in the thymus), while about 7 in 10 people with myasthenia gravis have thymic hyperplasia (enlargement of the thymus).
• Myasthenia gravis can affect people of any age, but it is more common in women under 50 in comparison to men. On the other hand, men aged 65 and older are more likely to have myasthenia gravis than women in the same age group. Overall, the condition is most common in people over the age of 50.
• It is reported that individuals of all races and ethnicities can be affected by myasthenia gravis, but it is observed to be slightly more common among people of African descent.

Country-wise Myasthenia Gravis Epidemiology

The myasthenia gravis epidemiology data and findings from the United States, Germany, Spain, Italy, France, the United Kingdom, Japan, and India are also provided in the epidemiology section.

The epidemiology of myasthenia gravis varies between countries owing to differences in genetic predisposition, environmental factors, healthcare systems, and diagnostic capabilities, affecting the prevalence, age of onset, and severity of the disease in different populations. In a study published in March 2023, researchers analyzed claims data from Germany and found that the incidence of myasthenia gravis in 2019 was 4.6 cases per 100,000 persons.

Scope of the Report

• The report covers a detailed analysis of signs and symptoms, causes, risk factors, pathophysiology, diagnosis, treatment options, and classification/types of myasthenia gravis based on several factors.
• Myasthenia Gravis Epidemiology Forecast Report covers data for the eight major markets (the US, France, Germany, Italy, Spain, the UK, Japan, and India).
• The report helps to identify the patient population and the unmet needs of myasthenia gravis are highlighted along with an assessment of the disease's risk and burden.

Key Questions Answered

• What are the key findings of myasthenia gravis epidemiology in the 8 major markets?
• What will be the total number of patients with myasthenia gravis across the 8 major markets during the forecast period?
• What was the country-wise prevalence of myasthenia gravis in the 8 major markets in the historical period?
• Which country will have the highest number of myasthenia gravis patients during the forecast period of 2025-2034?
• Which key factors would influence the shift in the patient population of myasthenia gravis during the forecast period of 2025-2034?
• What are the currently available treatments for myasthenia gravis?
• What are the disease risks, signs, symptoms, and unmet needs of myasthenia gravis?

This product will be delivered within 3-5 business days.